#### **Result Update**



29.0 %

2.9

Your success is our success

# **Birla Corporation**

Refer to important disclosures at the end of this report

# Capacity expansion to boost growth; maintain buy

- BCORP benefitted from higher sales volume and lower opex, which led to a 23% rise in EBITDA and 3.2pp improvement in OPM. Adjusted EBITDA stood at Rs3.6bn. OPM at 20.4% was in line with our estimate. Capacity utilization of its plants rose 4pp yoy to 92%.
- Key positives: 1) 29% yoy sales growth in premium products; 2) one of the best capacity utilization in the industry; 3) Rs730mn reduction in gross debt in 9MFY21 despite Rs7.3bn additional debt for new project; 4) 25.4% yoy/4% qoq reduction in interest expense as borrowing costs fell 1pp yoy. Volume grew 3.5% yoy. Realization fell 2.2% qoq.
- BCORP aims to achieve 25mt capacity by CY25. The 3.9mt Greenfield plant at Mukutban, Maharashtra, is likely to be commissioned by Q3FY22. Brownfield expansion of clinker capacity (0.4mt) at Chanderia, Rajasthan, will be completed in Q1FY22. Kundangani, UP expansion plan has been revived after being kept on hold due to Covid-19 issues.
- We raise FY21-23E EBITDA by 1-3% on higher volumes. We like BCORP due to 1) its capacity addition plans and 2) cost-saving initiatives - solar power plants and coal mining through acquired blocks. Maintain Buy on the stock.

Lower opex and higher sales volumes boost profits: BCORP benefited from lower opex (lower variable due to a decline in RM costs and employee costs) and higher sales volumes in Q3. Sales volume grew 3.5% yoy, leading to higher capacity utilization of 92% (up 4pp yoy). Sale of premium products was up 29% yoy and accounted for 53% of trade sales (up 12pp yoy). Cement realization was up 0.6% yoy, though it was down 2.2% gog as cement prices came under pressure in Q3. Revenue from the Jute business increased 31.7% yoy. Opex/ton fell 3.3% yoy due to a 10.5% yoy decline in variable cost/ton (impact of low RM costs). Employee expense/ton declined 5.2% yoy. Freight cost was up 1.4% yoy/3.2% qoq. Lower opex and higher sales volumes led to 23% yoy growth in EBITDA with 3.2pp improvement in OPM. EBITDA/ton stood at Rs992 vs. Rs850/Rs1,154 in Q3FY20/Q2FY21. The Jute business reported EBIT of Rs58.6mn vs. Rs43.7mn in Q3FY20. Lower interest rates (down 1pp yoy) and debt reduction (Rs41bn vs. Rs42.3bn at Mar'20) led to a 25.4% yoy decline in interest expense. Adjusted profit was up 83.4% yoy.

Maintain Buy considering capex plans and cost-saving initiatives: We raise FY21-23E EBITDA by 1-3% on higher volumes. BCORP operated its plants at much higher capacity utilization of 87% in FY20 despite volume loss in Mar'20. The company plans to increase its capacities by 5.1mt through 1) Greenfield unit of 3.9mt at Mukutban, Maharashtra, by Q3FY22, and 2) grinding capacity expansion of 1.2mt at its Kundangani, UP plant. It will increase clinker capacity at Chanderia, Rajasthan plant by 0.4mt through debottlenecking. We believe that capacity expansion in Maharashtra will help the company in geographical diversification. It will benefit from cost-saving strategies: 1) solar power plants will help cut cost by Rs10/ton; 2) coal mining from acquired mines will reduce cost by Rs68/ton; and 3) clinker transfer to existing grinding unit in Maharashtra from Mukutban will help achieve cost savings of Rs13/ton (on a blended basis). BCORP trades at 6.6x/5.6x FY22/23E EV/EBITDA and EV/ton of USD63, which appear attractive relative to its peers. We retain Buy with a TP of Rs930 (7x FY23E EV/EBITDA and post-tax incentives at a WACC of 11%). Key risks include a significant decline in cement prices and lower demand in key markets.

Please see our sector model portfolio (Emkay Alpha Portfolio): Cement & Building Materials (Page 8)

#### Financial Snapshot (Consolidated)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	65,487	69,240	67,101	76,094	84,117
EBITDA	9,486	13,443	13,457	14,127	15,879
EBITDA Margin (%)	14.5	19.4	20.1	18.6	18.9
APAT	2,557	5,135	5,013	5,012	5,727
EPS (Rs)	33.2	66.7	65.1	65.1	74.4
EPS (% chg)	53.6	100.8	(2.4)	0.0	14.3
ROE (%)	7.2	13.2	11.6	10.5	10.9
P/E (x)	21.7	10.8	11.1	11.1	9.7
EV/EBITDA (x)	9.3	6.5	6.6	6.6	5.6
P/BV (x)	1.5	1.3	1.2	1.1	1.0

Source: Company, Emkay Research

**CMP Target Price** Rs 930 (▲) Rs 721 as of (January 19, 2021) Rating **Upside** 

**BUY** (**■**)

Change in Estimates	
EPS Chg FY21E/FY22E (%)	5.7/2.3
Target Price change (%)	2.2
Target Period (Months)	12
Previous Reco	BUY
Emkay vs Consensus	

#### **EPS Estimates**

	FY21E	FY22E
Emkay	65.1	65.1
Consensus	64.4	68.7
Mean Consensus TP (	(12M)	Rs 1,008

Stock Details	
Bloomberg Code	BCORP IN
Face Value (Rs)	10
Shares outstanding (mn)	77
52 Week H/L	808 / 372
M Cap (Rs bn/USD bn)	56 / 0.76
Daily Avg Volume (nos.)	295,353

Snareholding Pattern Dec 20	)
Promoters	62.9%
FIIs	3.8%
DIIs	13.6%
Public and Others	19.7%

Daily Avg Turnover (US\$ mn)

Price Performance											
(%)	1M	3M	6M	12M							
Absolute	4	13	29	(3)							
Rel. to Nifty	(2)	(6)	-	(18)							

#### Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Sanieev Kumar Singh

sanjeev.singh@emkayglobal.com


+91 22 6612 1255

#### **Aman Jain**

aman.jain@emkayglobal.com +91 22 6612 1285


# **Story in Charts**

Exhibit 1: Sales volumes up 3.5% yoy



Source: Emkay Research, Company

Exhibit 3: Variable cost/ton down 10.5% yoy




Source: Emkay Research, Company

Exhibit 5: Freight cost/ton up 1.4% yoy/3.2% qoq




Source: Emkay Research, Company

Exhibit 7: OPM at 20.4%, up 3.2pp yoy/ down 2.7pp qoq




Source: Company, Emkay Research

Exhibit 2: Realization up 0.6% yoy, but down 2.2% qoq




Source: Emkay Research, Company

Exhibit 4: Energy cost/ton up 2.3% yoy




Source: Emkay Research, Company

Exhibit 6: Other expenses/ton up 5.7% yoy, but down 4.1% qoq



Source: Emkay Research, Company

Exhibit 8: EBITDA/ton at Rs1,005, up 18.6% yoy/ down 13.4% qoq



Source: Company, Emkay Research

# Exhibit 9: Actual vs. Estimates (Q3FY21)

(in Rs mn)	Actual			% va	riation	Comment
(III KS IIIII)	Actual	(Emkay)	(Consensus)	Emkay	Consensus	Comment
Sales	17,766	17,714	17,753	0.3	0.1	In-line with estimates
Adj. EBITDA	3,624	3,597	3,571	0.8	1.5	In-line with estimates
EBITDA margin (%)	20.4	20.3	20.1	9bps	28bps	
Adj. PAT	1,495	1,429	1,432	4.6	4.4	In-line with estimates

Source: Company, Emkay Research

## **Exhibit 10: Quarterly result**

Rs mn	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	YoY (%)	QoQ (%)	9MFY20	9MFY21	YoY %
Revenue	17,151	16,900	12,220	16,543	17,766	3.6	7.4	52,257	46,528	(11.0)
Expenditure	14,205	13,453	9,889	12,716	14,143	(0.4)	11.2	42,344	36,747	(13.2)
as % of sales	82.8	79.6	80.9	76.9	79.6			81.0	79.0	
Consumption of RM	3,598	2,427	2,536	2,204	2,918	(18.9)	32.4	9,269	7,658	(17.4)
as % of sales	21.0	14.4	20.8	13.3	16.4			17.7	16.5	
Employee Expenses	1,047	976	880	1,008	1,028	(1.9)	2.0	3,103	2,915	(6.0)
as % of sales	6.1	5.8	7.2	6.1	5.8			5.9	6.3	
Power, Oil & Fuel	3,152	3,311	2,086	3,173	3,336	5.8	5.1	10,498	8,595	(18.1)
as % of sales	18.4	19.6	17.1	19.2	18.8			20.1	18.5	
Freight & Handling	3,346	3,513	2,157	3,123	3,511	5.0	12.4	10,232	8,792	(14.1)
as % of sales	19.5	20.8	17.7	18.9	19.8			19.6	18.9	
Other Expenses	3,062	3,226	2,230	3,207	3,350	9.4	4.4	9,242	8,787	(4.9)
as % of sales	17.9	19.1	18.2	19.4	18.9			17.7	18.9	
EBITDA	2,946	3,446	2,331	3,827	3,624	23.0	(5.3)	9,913	9,782	(1.3)
Depreciation	884	894	877	918	908	2.7	(1.1)	2,625	2,702	2.9
EBIT	2,063	2,553	1,455	2,909	2,716	31.7	(6.6)	7,288	7,079	(2.9)
Other Income	203	281	190	212	146	(28.1)	(30.9)	571	548	(3.9)
Interest	977	909	800	760	730	(25.4)	(4.0)	2,967	2,289	(22.9)
PBT	1,289	1,924	845	2,361	2,133	65.5	(9.7)	4,892	5,339	9.1
Total Tax	474	99	188	694	638	34.7	(8.1)	1,787	1,520	(14.9)
Adjusted PAT	815	1,825	658	1,666	1,495	83.4	(10.3)	3,105	3,819	23.0
Extra ordinary items	-	(122)	-	-	(11)	n/m	n/m	-	(11)	n/m
Reported PAT	815	1,703	658	1,666	1,484	82.1	(10.9)	3,105	3,808	22.7
Adjusted EPS (Rs)	10.6	23.7	8.5	21.6	19.4	83.4	(10.3)	40.3	49.6	23.0

Margins (%)						bps	bps			bps
EBITDA	17.2	20.4	19.1	23.1	20.4	322	(274)	19.0	21.0	205
EBIT	12.0	15.1	11.9	17.6	15.3	326	(230)	13.9	15.2	127
EBT	7.5	11.4	6.9	14.3	12.0	449	(227)	9.4	11.5	211
PAT	4.8	10.8	5.4	10.1	8.4	366	(166)	5.9	8.2	227
Effective Tax rate	36.8	5.1	22.2	29.4	29.9	(684)	50	36.5	28.5	(806)

Source: Company, Emkay Research

#### Exhibit 11: Operating cost analysis on per ton basis

Particulars (Rs/ton)	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	YoY (%)	QoQ (%)	9MFY20	9MFY21	YoY %
Cement Volumes (mt)	3.43	3.30	2.40	3.26	3.55	3.5	8.9	10.2	9.2	(10.0)
Raw Material Consumed	1,049	735	1,057	676	822	(21.6)	21.6	906	831	(8.2)
Employee Expenses	305	296	367	309	289	(5.2)	(6.4)	303	317	4.4
Power, Oil & Fuel	919	1,003	869	973	940	2.3	(3.5)	1,026	933	(9.1)
Freight	975	1,065	899	958	989	1.4	3.2	1,000	955	(4.6)
Other Expenses	647	754	776	803	725	12.1	(9.7)	663	766	15.5
Total Cost	3,895	3,853	3,967	3,720	3,765	(3.3)	1.2	3,899	3,802	(2.5)
Realization	4,743	4,889	4,956	4,880	4,770	0.6	(2.2)	3,264	3,019	(7.5)
EBITDA	847	1,036	989	1,160	1,005	18.6	(13.4)	(635)	(783)	23.3

Source: Company, Emkay Research

Exhibit 12: Changes in estimates

Particulars (Rs mn)		FY21E			FY22E			FY23E	
r articulars (NS IIII)	Revised	Previous	Chg (%)	Revised	Previous	Chg (%)	Revised	Previous	Chg (%)
Sales volume -mt	13.1	12.8	2.1	14.9	14.6	2.0	16.2	15.9	2.0
Realization Rs/ton)	4,756	4,756	-	4,766	4,777	(0.2)	4,848	4,858	(0.2)
Sales	67,101	65,775	2.0	76,094	74,833	1.7	84,117	82,754	1.6
EBITDA	13,457	13,097	2.8	14,127	13,976	1.1	15,879	15,720	1.0
OPM (%)	20.1	19.9	14.4	18.6	18.7	(11.0)	18.9	19.0	(11.9)
Profit	5,013	4,745	5.7	5,012	4,899	2.3	5,727	5,609	2.1
EPS (Rs)	65.1	61.6	5.7	65.1	63.6	2.3	74.4	72.8	2.1

Source: Company, Emkay Research

**Exhibit 13: Key Assumptions** 

Key Assumptions	FY18	FY19	FY20	FY21E	FY22E	FY23E
•						
Sales Volumes (mt)	12.3	13.8	13.7	13.1	14.9	16.2
Realization (Rs/ton)	4,061	4,359	4,682	4,756	4,766	4,848
Per ton costs (Rs)						
Raw material	926	943	845	1,006	1,012	1,003
Employee cost	289	268	299	294	282	279
Power & Fuel	1,055	1,073	1,012	1,034	1,078	1,100
Freight	960	980	1,007	1,006	1,012	1,003
<b>Total Cost</b>	3,986	4,047	4,088	4,096	4,166	4,201
EBITDA	654	686	988	1,028	950	977


Source: Company, Emkay Research

**Exhibit 14: Peer Valuation** 

	Rs bn	EV/	EBITDA (x)		EV	/Ton (USD)			P/E (x)	
Company	Мсар	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E	FY21E	FY22E	FY23E
Birla Corp	56	6.6	6.6	5.6	76	63	57	11.1	11.1	9.7
UltraTech Cement	1,598	15.5	14.3	12.2	195	185	174	29.3	26.3	22.1
Shree Cements	855	22.3	19.4	16.9	254	237	231	48.2	42.3	37.2
Ambuja Cements*	512	15.5	14.5	12.1	183	168	161	28.9	28.5	24.6
ACC*	319	10.6	9.3	8.6	106	104	104	23.2	20.4	18.7
Ramco Cements	191	14.0	13.7	12.0	147	138	132	22.9	23.6	20.6
JK Cement	162	13.1	12.5	11.0	147	145	142	28.7	26.2	22.0
India Cements	52	10.6	9.9	8.6	72	69	66	26.8	25.1	19.5
Prism Cement	42	11.5	10.7	9.1	106	107	105	54.3	45.3	28.5
Star Cement	41	10.3	7.9	7.0	94	88	84	16.2	13.2	12.4
JK Lakshmi Cement	38	6.4	5.9	5.3	50	47	44	14.5	13.1	11.7
Orient Cement	17	5.5	5.8	5.1	44	42	39	10.3	12.3	10.5


Source: Company, Emkay Research

Exhibit 15: 1-yr forward EV/EBITDA chart



Source: Bloomberg, Company, Emkay Research

Exhibit 16: 1-yr forward EV/ton chart



Source: Bloomberg, Company, Emkay Research

# Key Financials (Consolidated)

#### **Income Statement**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	65,487	69,240	67,101	76,094	84,117
Expenditure	56,001	55,797	53,643	61,966	68,238
EBITDA	9,486	13,443	13,457	14,127	15,879
Depreciation	3,391	3,519	3,608	4,098	4,769
EBIT	6,095	9,924	9,850	10,030	11,110
Other Income	785	851	796	812	828
Interest expenses	3,705	3,877	3,911	4,109	4,245
PBT	3,174	6,898	6,735	6,733	7,693
Tax	617	1,763	1,722	1,721	1,967
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	2,557	5,135	5,013	5,012	5,727
Adjusted PAT	2,557	5,135	5,013	5,012	5,727

# **Balance Sheet**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	770	770	770	770	770
Reserves & surplus	44,182	48,621	52,938	57,579	62,748
Net worth	44,952	49,391	53,708	58,349	63,519
Minority Interest	0	0	0	0	0
Loan Funds	40,492	42,260	42,760	46,560	43,760
Net deferred tax liability	7,422	8,568	8,568	8,568	8,568
Total Liabilities	92,866	100,219	105,036	113,477	115,847
Net block	72,633	73,256	75,006	95,308	100,540
Investment	8,778	8,362	6,372	5,872	5,872
Current Assets	21,813	25,428	27,793	28,309	29,733
Cash & bank balance	1,390	3,888	4,442	5,176	5,676
Other Current Assets	0	0	0	0	0
Current liabilities & Provision	20,450	22,865	23,173	23,051	23,337
Net current assets	1,364	2,563	4,619	5,258	6,396
Misc. exp	0	0	0	0	0
Total Assets	92,866	100,219	105,036	113,477	115,847

## **Cash Flow**

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	3,174	6,898	6,735	6,733	7,693
Other Non-Cash items	(470)	0	0	0	0
Chg in working cap	1,309	1,299	(1,502)	96	(639)
Operating Cashflow	10,641	14,975	11,030	13,314	14,101
Capital expenditure	(4,197)	(10,088)	(8,358)	(12,400)	(6,000)
Free Cash Flow	6,444	4,887	2,672	914	8,101
Investments	(2,271)	416	1,990	500	0
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(5,434)	(9,672)	(6,368)	(11,900)	(6,000)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(1,297)	1,768	500	3,800	(2,800)
Dividend paid (incl tax)	(603)	(696)	(696)	(371)	(557)
Other Financing Cash Flow	0	0	0	0	0
Financing Cashflow	(5,349)	(2,805)	(4,107)	(680)	(7,602)
Net chg in cash	(141)	2,498	554	734	499
Opening cash position	1,036	1,390	3,888	4,442	5,176
Closing cash position	1,390	3,888	4,442	5,176	5,676

Source: Company, Emkay Research

nev Ralios	Ke۱	Ratios
------------	-----	--------

Profitability (%)	FY19	FY20	FY21E	FY22E	FY23E
EBITDA Margin	14.5	19.4	20.1	18.6	18.9
EBIT Margin	9.3	14.3	14.7	13.2	13.2
Effective Tax Rate	19.4	25.6	25.6	25.6	25.6
Net Margin	3.9	7.4	7.5	6.6	6.8
ROCE	8.2	12.2	11.3	10.7	11.2
ROE	7.2	13.2	11.6	10.5	10.9
RoIC	9.3	15.5	15.1	13.0	12.3

Per Share Data (Rs)	FY19	FY20	FY21E	FY22E	FY23E
EPS	33.2	66.7	65.1	65.1	74.4
CEPS	77.2	112.4	111.9	118.3	136.3
BVPS	477.1	534.7	590.8	651.0	718.1
DPS	7.5	7.5	4.0	6.0	7.0

Valuations (x)	FY19	FY20	FY21E	FY22E	FY23E
PER	21.7	10.8	11.1	11.1	9.7
P/CEPS	9.3	6.4	6.4	6.1	5.3
P/BV	1.5	1.3	1.2	1.1	1.0
EV / Sales	1.4	1.3	1.3	1.2	1.1
EV / EBITDA	9.3	6.5	6.6	6.6	5.6
Dividend Yield (%)	1.0	1.0	0.6	0.8	1.0

Gearing Ratio (x)	FY19	FY20	FY21E	FY22E	FY23E
Net Debt/ Equity	0.9	0.8	0.7	0.7	0.6
Net Debt/EBIDTA	3.5	2.4	2.5	2.6	2.1
Working Cap Cycle (days)	(0.1)	(7.0)	1.0	0.4	3.1

Growth (%)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	14.3	5.7	(3.1)	13.4	10.5
EBITDA	17.4	41.7	0.1	5.0	12.4
EBIT	28.1	62.8	(0.7)	1.8	10.8
PAT	42.9	100.8	(2.4)	0.0	14.3

Quarterly (Rs mn)	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21
Revenue	17,151	16,900	12,220	16,543	17,766
EBITDA	2,946	3,446	2,331	3,827	3,624
EBITDA Margin (%)	17.2	20.4	19.1	23.1	20.4
PAT	815	1,947	658	1,666	1,505
EPS (Rs)	10.6	25.3	8.5	21.6	19.5

Source: Company, Emkay Research

Shareholding Pattern (%)	Dec-19	Mar-20	Jun-20	Sep-20	Dec-20
Promoters	62.9	62.9	62.9	62.9	62.9
FIIs	3.9	4.2	3.6	3.4	3.8
DIIs	15.5	15.3	14.6	15.2	13.6
Public and Others	17.8	17.6	18.9	18.6	19.7


Source: Capitaline

#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
05-Nov-20	643	895	12m	Buy	Sanjeev Kumar Singh
16-Oct-20	639	895	12m	Buy	Sanjeev Kumar Singh
28-Sep-20	656	779	12m	Buy	Sanjeev Kumar Singh
09-Aug-20	653	779	12m	Buy	Sanjeev Kumar Singh
22-May-20	407	647	12m	Buy	Sanjeev Kumar Singh
18-May-20	387	469	12m	Buy	Sanjeev Kumar Singh
26-Apr-20	412	469	12m	Buy	Sanjeev Kumar Singh
01-Apr-20	418	526	12m	Buy	Sanjeev Kumar Singh
28-Jan-20	731	967	12m	Buy	Sanjeev Kumar Singh

Source: Company, Emkay Research

## RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

# **Emkay Alpha Portfolio – Cement & Building Materials**



**Analyst: Sanjeev Kumar Singh** 

#### **Contact Details**

sanjeev.singh@emkayglobal.com +91 22 6612 1255

#### Sector

Cement & Building materials

#### Analyst bio

Sanjeev Kumar Singh holds an MBA and has over 10 years of experience in the Cement sector. His team currently covers 17 stocks in the Cement and Building Materials space.

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Cement & Building Materials	2.10	2.10	0%	0	100.00
ACC	0.17	0.00	-100%	-17	0.00
Ambuja Cements	0.23	0.25	9%	2	11.91
Grasim Industries	0.50	0.49	0%	0	23.54
Birla Corporation	0.00	0.04	NA	4	1.91
India Cements	0.00	0.00	NA	0	0.00
JK Cement	0.00	0.00	NA	0	0.00
Jk Lakshmi Cement	0.00	0.04	NA	4	1.97
Orient Cement	0.00	0.00	NA	0	0.00
Prism Johnson	0.00	0.00	NA	0	0.00
Ramco Cements	0.13	0.14	10%	1	6.58
Shree Cements	0.29	0.28	0%	0	13.57
Star Cement	0.00	0.00	NA	0	0.00
Ultratech Cement	0.79	0.85	8%	6	40.52
Century Plyboards	0.00	0.00	NA	0	0.00
Kajaria Ceramics	0.00	0.00	NA	0	0.00
Somany Ceramics	0.00	0.00	NA	0	0.00
Cash	0.00	0.00	NΔ	0	0.00

Source: Emkay Research

**EAP** sector portfolio

■ High Conviction/Strong Over Weight

#### Sector portfolio NAV

Base						Latest
	1-Apr-19	23-Jan-20	23-Jul-20	22-Oct-20	22-Dec-20	21-Jan-21
EAP - Cement & Building Materials	100.0	106.4	90.1	106.1	111.7	121.2
BSE200 Neutral Weighted Portfolio (ETF)	100.0	103.2	87.1	103.9	110.5	119.9

<sup>\*</sup>Performance measurement base date 1st April 2019


Source: Emkay Research

## Price Performance (%)

	1m	3m	6m	12m
EAP - Cement & Building Materials	8.5%	14.2%	34.5%	13.8%
BSE200 Neutral Weighted Portfolio (ETF)	8.5%	15.4%	37.7%	16.2%

Source: Emkay Research

# NAV chart



Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

<sup>\*</sup> Not under coverage: Equal Weight

#### **Emkay Rating Distribution**

Ratings	Expected Return within the next 12-18 months.		
BUY	Over 15%		
HOLD	Between -5% to 15%		
SELL	Below -5%		

Completed Date: 25 Jan 2021 11:30:28 (SGT) Dissemination Date: 25 Jan 2021 11:31:28 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

#### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on the sender. Further, this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

# ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of January 25, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research
  report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment
  recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of January 25, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the January 25, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the January 25, 2021

<sup>&</sup>lt;sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## **RESTRICTIONS ON DISTRIBUTION**

INEO I INIO I I ONO ON E	SIGHT ADD THOM
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
United Kingdom	In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

# Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com